Featured
Kahn Swick & Foti, LLC and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Bristol-Myers Squibb Company Class: Investors who received Contingent Value Rights in exchange for their shares of Celgene Corporation pursuant to Bristol-Myers’ acquisition of Celgene on November 20, 2019 Lead Plaintiff Motion ...

Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:

Bristol-Myers Squibb Company (BMY)
Class: Investors who received Contingent Value Rights ("CVRs") (BMY.RT) in exchange for their shares of Celgene Corporation (CELG) pursuant to Bristol-Myers' acquisition of Celgene on November 20, 2019
Lead Plaintiff Motion Deadline: December 6, 2021
MISLEADING PROSPECTUS
To learn more, visit https://www.ksfcounsel.com/cases/nyse-bmy/

read more Show less
GoviEx Uranium Inc. announces that, pursuant to its Share Purchase Option Plan, it has granted incentive stock options to the Company's Head of IR and Corporate Communications to purchase up to an aggregate of 500,000 Class A common shares in the capital stock of GoviEx.The stock options are exercisable at a price of $0.39 per share and will vest 25% on the date of grant and thereafter, 25% on each anniversary of ...

GoviEx Uranium Inc. (TSXV: GXU) (OTCQX: GVXXF) ("GoviEx" or the "Company"), announces that, pursuant to its Share Purchase Option Plan, it has granted incentive stock options to the Company's Head of IR and Corporate Communications to purchase up to an aggregate of 500,000 Class A common shares in the capital stock of GoviEx.

The stock options are exercisable at a price of $0.39 per share and will vest 25% on the date of grant and thereafter, 25% on each anniversary of the date of grant until fully vested. The options expire on December 1, 2026.

read more Show less
ClaimsFiler, a FREE shareholder information service, reminds investors with losses in excess of $100,000 that they have until December 6, 2021 to file lead plaintiff applications in a securities class action lawsuit against Bristol-Myers Squibb Company if they received Contingent Value Rights in exchange for their shares of Celgene Corporation pursuant to BMS' acquisition of Celgene on November 20, 2019 . This ...

- ClaimsFiler, a FREE shareholder information service, reminds investors with losses in excess of $100,000 that they have until December 6, 2021 to file lead plaintiff applications in a securities class action lawsuit against Bristol-Myers Squibb Company ("BMS" or "the Company") (NYSE: BMY), if they received Contingent Value Rights ("CVRs") (NYSE: BMY.RT) in exchange for their shares of Celgene Corporation (NASDAQ: CELG) pursuant to BMS' acquisition of Celgene on November 20, 2019 . This action is pending in the United States District Court for the Southern District of New York .

Get Help
BMS investors should visit us at https://claimsfiler.com/cases/nyse-bmy-3/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

read more Show less

MARKETS

Markets
TSX20464.60-195.39
TSXV917.92-21.52
DOW34022.04-461.68
S&P 5004513.04-53.96
NASD15254.05-283.64
ASX7235.90-20.10

COMMODITIES

Commodities
Gold1772.48-9.35
Silver22.34-0.02
Copper4.26+0.02
Palladium1748.18-2.81
Platinum940.88+4.88
Oil66.40+0.83
Heating Oil2.10+0.03
Natural Gas4.25-0.01